9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 82

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Overall Survival,  Progression Free Survival,  Response Rate, Toxicity- incidence of adverse events

Interventions: NovoTTF-100L device, Pemetrexed

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: April 2018

Completion Date: April 2018

Last  Posted Date: September 25, 2018

Location: Antwerp University Hospital, Thoracic Oncology, Antwerp, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT02397928

Was this article helpful?
Dislike 0